Market chat

Celltrion

068270, KOSPI, Healthcare

₩180,400▲ ₩808+0.45%2026-10-12 close
Prev. close
₩179,592
Volume
386.2K
Market cap
₩42T
  • -28% from high
  • Low-volatility blue chip

Stock and sector context

Healthcareoutflow
Sector comparison
Celltrion changed +0.45%. The 13 covered Healthcare stocks in Korean averaged -3.35%, with estimated sector flow of outflow.
Variables to watch
Drug approvals and trial resultsDrug pricing policyUS interest ratesUSD/KRW
Risks to check
  • -28% below the high, the downtrend may continue
  • Clinical trial failure
  • Drug pricing pressure

This compares price changes among covered stocks in the same market. It does not establish why prices moved. Variables and risks are sector reference lists.

Why a candidate

Match 58/100

The match score marks how many conditions overlap on a 0 to 100 scale: the 52-week range, valuation metrics, price change and volume. It is not a probability of rising or a forecast return.

vs 52w high -28%OversoldInflow index

Today's read

Celltrion scores 58 out of 100 on today's InverseOne match ranking, 4 of 60 in the Korean large-cap universe. The gap to its 52-week high is 39%. Today's move of +0.45% came with money flowing in, alongside the Healthcare sector. Scores are estimates built from price and volume, a starting point for research rather than a trading signal.

Data basis: 2026-10-12 close, 10-14 00:20 KST updated, For reference only, not advice

Lending balance

Little change

6,855,837 sh

KRW 1.24T

1D -0.20%5D -4.23%

New 11,458 sh, Returned 25,103 sh

Shares borrowed through securities lending that have not yet been returned. Borrowed shares are often sold afterwards, so the balance is used as a reference for pending sell pressure.

As of 2026-10-12, FSC stock lending data

Company profile

Unqualified opinion

(주)셀트리온

CEO
기우성, 서진석
Employees
3,153
Average tenure
6.2 years
Average pay per employee
₩107M
Listed
2018-02-09
Founded
1991-02-27
Auditor
삼일회계법인

As filed 2026-10-12

Company site

Talk about this stock

New thread

Today's talking points

  • It sits low in its 52-week range (24).
  • It is 39% below its 52-week high.

Three months out, which way do you see it?

Nobody has answered yet. Sign in to be the first.

These are answers picked by members, not investment advice.

Fund-flow signal

Inflow index+₩313.5M

Net flow, Inflow

Market flow rank
Inflow #4 of 7
Sector flow rank
#1 of 13

Today's overlaps

Near 52w low + inflow index

Trend building (not enough trading days)

Market data

52-week range
₩158,500 ~ ₩251,000
52-week position24/100
₩158,500₩251,000
Gap to 52w high+39.1%

AI zone read

Worth watchingCondition score 64

Evidence

  • Near the low24
  • Gap to the high39.1
  • How firm the news is4.0

This formula has not passed after-the-fact validation yet. Its results are being collected on the record page.

AI reads the headlines; the zone comes from a published formula.

See the formula

Related news

From the headlinesAmount and schedule stated

Same-sector stocks

Sam Chun Dang Pharm000250, Healthcare-12.73%LigaChem Biosciences141080, Healthcare-5.73%ST Pharm237690, Healthcare-4.20%ALTEOGEN196170, Healthcare-3.94%Lunit328130, Healthcare-3.34%HLB028300, Healthcare-2.74%CLASSYS214150, Healthcare-2.64%HK inno.N195940, Healthcare-2.52%

These figures are reference estimates built from price and volume: a starting point for narrowing down ideas, not a buy or sell signal.